Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 7/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | STAT5B | P51692 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616508 | 0.73 | NR1D1 (0.32) | NR1D1NR1H3 | |
| SCHEMBL6126681 | 0.73 | NR1D1 (0.32) | NR1D1 | |
| SCHEMBL7707821 | 0.73 | AKT1 (0.48) | STAT5BALDH1A1SMN1; SMN2 | |
| SCHEMBL7705112 | 0.71 | STAT5B (0.46) | STAT5BKMT2A | |
| SCHEMBL335791 | 0.71 | HTR2C (0.38) | NR1D1STAT5BMAPTMEN1ALDH1A1 | |
| SCHEMBL7705341 | 0.70 | TSHR (0.40) | STAT5BMAPTSMN1; SMN2 | |
| SCHEMBL6338886 | 0.70 | TAS2R14 (0.42) | NR1D1NR1H3MAPTMEN1ALDH1A1 | |
| SCHEMBL7702197 | 0.70 | RIPK1 (0.43) | NR1D1 | |
| SCHEMBL7705226 | 0.68 | RIPK1 (0.48) | — | |
| SCHEMBL7707801 | 0.68 | KMT2A (0.43) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2421845-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LAB (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2421845-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010111437-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | NR1D1 3256/4885NR1H3 2531/4885STAT5B 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.